Associated Genetic Biomarkers
NCI Definition: A carcinoma of the ureter. The majority of ureter carcinomas are transitional cell and less frequently squamous cell carcinomas or adenocarcinomas. --2003 
There are 5 clinical trials for ureter carcinoma, of which 4 are open and 1 is completed or closed. Of the trials that contain ureter carcinoma as an inclusion criterion, 2 are phase 1 (1 open) and 3 are phase 2 (3 open).
ERBB2 is the most frequent gene inclusion criterion for ureter carcinoma clinical trials .
Nivolumab, ado-trastuzumab emtansine, and cabozantinib are the most common interventions in ureter carcinoma clinical trials.
Significant Genes in Ureter Carcinoma
EGFR is an inclusion eligibility criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
ERBB2 is an inclusion eligibility criterion in 2 clinical trials for ureter carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and ureter carcinoma as inclusion criteria, 2 are phase 2 (2 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.